Pharmaceutical companies share the goal of patient benefit with healthcare professionals. However, they are commercial organizations and hence, sometimes, commercial interest may take over science, resulting in “science-commercial disconnect”. This can result in innovation-deficit and financial burden on the patients. Finding new indications for existing drugs and promoting academic research in ‘non-profitable areas’ are some measures to curtail pharmaceutical innovation-deficit. Greater involvement of academicians and non-government organizations in clinical research with government support/funding will help in providing best treatment options to the patients for better outcomes.
Academic research, Financial profit, Patient centricity, Science-commercial disconnect